4584 Kidswell Bio Corporation - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4584

TSE Growth

Kidswell Bio Corporation

115

JPY

(+3.60%)

Apr 11, 3:30 pm JST

0.79

USD

Apr 11, 2:30 am EDT

Result

PTS

outside of trading hours

114

Apr 11, 9:42 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	996	-969	-991	-1,001	-34.8	0	May 13, 2021	J-GAAP
Mar, 2022	1,569	-919	-952	-535	-17.4	0	May 12, 2022	J-GAAP
Mar, 2023	2,776	-550	-624	-657	-20.8	0	May 12, 2023	J-GAAP
Mar, 2024	2,431	-1,335	-1,389	-1,422	-40.2	0	May 14, 2024	J-GAAP
Mar, 2025 Guidance	4,900	-150	-200	-200	-4.9	0	Mar 31, 2025	J-GAAP
YoY	+101.6%	+88.8%	+85.6%	+85.9%	+87.7%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 25, 2020	972	-1,672	-1,688	-1,691	0	J-GAAP
Results	May 13, 2021	996	-969	-991	-1,001	0	J-GAAP
Mar, 2022	May 13, 2021	Available in future release
	Oct 21, 2021
Results	May 12, 2022
Mar, 2023	May 12, 2022
Results	May 12, 2023
Results	ー
Mar, 2024	May 12, 2023
	Mar 25, 2024
Results	May 14, 2024
Mar, 2025	May 14, 2024	4,000	ー	ー	ー	0	J-GAAP
- - -	Nov 12, 2024	4,000	-1,000	-1,000	-950	0	J-GAAP
	Mar 31, 2025	4,900	-150	-200	-200	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2008	200	－	Available in future release
Mar, 2009	205	+2.5
Mar, 2010	92	-55.1
Mar, 2011	109	+18.5
Mar, 2012	207	+89.9
Mar, 2013	60	-71.0
Mar, 2014	301	+401.7
Mar, 2015	321	+6.6
Mar, 2016	1,160	+261.4
Mar, 2017	1,089	-6.1
Mar, 2018	1,059	-2.8
Mar, 2019	1,021	-3.6
Mar, 2020	1,077	+5.5
Mar, 2021	996	-7.5
Mar, 2022	1,569	+57.5
Mar, 2023	2,776	+76.9
Mar, 2024	2,431	-12.4
Mar, 2025 Guidance	4,900	+101.6	-150	+88.8	-200	+85.6	-4.9	+87.8

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	2,776	-550	-20	-51.13	-17.76	0.75	-20.8
Mar, 2024	2,431	-1,335	-55	-166.71	-31.67	0.54	-40.2
Mar, 2025 Guidance	4,900	-150	-3.1	-20.64	-4.37	1.07	-4.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	2,776	-316	-88	-89	-17.4
Fiscal Year	Mar, 2023	Mar, 2012	Mar, 2008	Mar, 2008	Mar, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	829	-469	-489	-72	-2.3	0	May 12, 2022	J-GAAP
Oct - Mar, 2022	1,660	-561	-582	-615	-19.4	0	May 12, 2023	J-GAAP
Oct - Mar, 2023	1,850	-616	-645	-642	-18.2	0	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	3,151	112	67	41	1.0	0	Mar 31, 2025	J-GAAP
YoY	+70.3%	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	-919	-643	-1,169	526	369	1,187	33.89	J-GAAP
Mar, 2023	-550	-1,449	-1,421	-28	1,356	1,067	27.40	J-GAAP
Mar, 2024	-1,335	ー	-453	ー	1,617	2,231	43.87	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	1,726	-135	-194	-194	-6.2	ー	Feb 7, 2023	J-GAAP
Apr - Dec, 2023	1,566	-667	-712	-747	-21.8	ー	Feb 7, 2024	J-GAAP
Apr - Dec, 2024	3,036	-137	-161	-187	-4.7	ー	Feb 12, 2025	J-GAAP
YoY	+93.9%	+79.5%	+77.4%	+75.0%	+78.5%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2023	1,050	-415	-430	-463	-14.6	-39.5	May 12, 2023	J-GAAP
Apr - Jun, 2023	45	-455	-470	-470	-14.7	-1,011.1	Aug 7, 2023	J-GAAP
Jul - Sep, 2023	536	-264	-274	-310	-9.6	-49.3	Nov 8, 2023	J-GAAP
Oct - Dec, 2023	985	52	32	33	1.0	5.3	Feb 7, 2024	J-GAAP
Jan - Mar, 2024	865	-668	-677	-675	-19.1	-77.2	May 14, 2024	J-GAAP
Apr - Jun, 2024	482	-158	-176	-176	-4.5	-32.8	Aug 14, 2024	J-GAAP
Jul - Sep, 2024	1,267	-104	-91	-65	-1.6	-8.2	Nov 12, 2024	J-GAAP
Oct - Dec, 2024	1,287	125	106	54	1.4	9.7	Feb 12, 2025	J-GAAP
YoY	+30.7%	+140.4%	+231.3%	+63.6%	+40.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2020	344	-14.6	Available in future release
Apr - Jun, 2020	121	-57.2
Jul - Sep, 2020	53	+76.7
Oct - Dec, 2020	546	+30.0
Jan - Mar, 2021	276	-19.8
Apr - Jun, 2021	303	+150.4
Jul - Sep, 2021	437	+724.5
Oct - Dec, 2021	643	+17.8
Jan - Mar, 2022	186	-32.6
Apr - Jun, 2022	610	+101.3
Jul - Sep, 2022	506	+15.8
Oct - Dec, 2022	610	-5.1
Jan - Mar, 2023	1,050	+464.5
Apr - Jun, 2023	45	-92.6
Jul - Sep, 2023	536	+5.9
Oct - Dec, 2023	985	+61.5
Jan - Mar, 2024	865	-17.6
Apr - Jun, 2024	482	+971.1
Jul - Sep, 2024	1,267	+136.4
Oct - Dec, 2024	1,287	+30.7	125	+140.4	106	+231.3	1.4	+40.0

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,287	125	106	369	12.1
Fiscal Year	Dec, 2024	Dec, 2024	Dec, 2024	Dec, 2021	Dec, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	48.79	43.8	3,503	1,533	-10,613	0.46	May 12, 2022	J-GAAP
Mar, 2023	32.36	26.6	3,894	1,037	-11,287	1.88	May 12, 2023	J-GAAP
Mar, 2024	21.35	13.2	5,085	669	-12,709	3.85	May 14, 2024	J-GAAP
Apr - Dec, 2024	ー	21.2	4,574	969	-12,896	2.10	Feb 12, 2025	J-GAAP

Kidswell Bio Corporation(4584) Financial Results